General principles for treatment selection Jeffrey Myers MD PhD.

Slides:

Advertisements

Similar presentations

Advertisements

Pulmonary Stereotactic Ablative Radiotherapy:

Management of locally advanced & metastatic prostate cancer Dr. Purvish. M. Parikh MD, DNB, PhD, FICP Professor & Head Department of Medical Oncology Tata.

DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT.

Neck Cancer Head and STATEMENTS ON January 28, 2006 Frankfurt am Main, Germany Surgery Surgery in Multimodal Treatment.

Author : Updated : HPV Associated Oropharyngeal Cancer Benjamin L. Judson, M.D. 10/19/ Cedar Street New Haven, Connecticut

Breast Cancer in Pregnancy

CA Esophagus – Role of Chemoirradiation WH Chan Pamela Youde Nethersole Eastern Hospital.

Surgical Management of Oropharyngeal Cancers Kerry D. Olsen, M.D. Professor, Otolaryngology Head and Neck Surgery Mayo Clinic Kerry D. Olsen, M.D. Professor,

AJCC Staging Moments AJCC TNM Staging 7th Edition Glottic Larynx Case #1 Contributors: Jatin P. Shah, MD Memorial Sloan-Kettering Cancer Center, New York,

V. Budach – Statements on H&N Cancer - 1 Discussion Panel on Primary Radiochemotherapy Volker Budach, MD, PhD Head Department for Radiation Oncology Charité.

Indications for adjuvant radiation therapy with or without lymph nodes in salivary gland cancer Claus Rödel Department of Radiation Therapy University.

Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.

Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.

Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

IMRT for the Treatment of Anal Cancer Kristen O’Donnell, MS3 December 12, 2007.

Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

AJCC Staging Moments AJCC TNM Staging 7th Edition Supraglottic Larynx Case #2 Contributors: Jatin P. Shah, MD Memorial Sloan-Kettering Cancer Center, New.

CLINICAL PRACTICE GUIDELINES Connective Tissue Oncology Society 2005 Meeting, Boca Raton Vivien Bramwell Chair, NCIC-CTG Sarcoma Committee Canadian Sarcoma.

Mark L. Merlin, M.D. Radiotherapy Clinics of Georgia 7/14/2010 The Role of Radiation Therapy in the Management of Prostate Cancer.

Definitive radiotherapy for head and neck cancer: the use of physical exam versus computed tomography to manage the post-RT neck Stanley Liauw*, Robert.

STATEMENTS 2008 on Head and Neck Cancer Stephane TEMAM, M.D. PhD. Department of Head and Neck Surgery Mucosal Melanoma.

Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.

Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:

Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer Jacques Bernier, M.D., Ph.D., Christian Domenge,

Adjuvant radiochemotherapy in head and neck tumors H. Christiansen and C. F. Hess Department of Radiotherapy Goettingen University.

Comparison of SIB-IMRT and Conventional Accelerated Hyper-fractionated IMRT With Concurrent Cisplatin and Etoposide for Limited Disease SCLC Baosheng Li.

Intensity-Modulated Radiotherapy is Associated with Improved Global Quality of Life Among Long-Term Survivors of Head and Neck Cancer Allen M. Chen, M.D.,

Workshop on Advanced Technologies in Radiation Oncology Kian Ang.

Taipei VGH Practice Guidelines: Oncology Guidelines Index Cancer of Oral Cavity Version Table of Content StagingStaging, Manuscript Taipei Veterans.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.

Cancer of the Head and Neck and HPV Infection Andrew Urquhart MD, FACS Dept. Otolaryngology/Head and Neck Surgery Marshfield Clinic.

Head & Neck Ca. (Epithelial tumors) Mohamad KADRI. MD. Clinical oncology. Medical director of AlBerouni University Hospital President of Syrian Association.

Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer V. Heinemann*, M. Haas & S. Boeck Annals of Oncology 24: 2484–2492,

HPV-Related Head and Neck Squamous Cancers Bruce H. Campbell, MD FACS Medical College of Wisconsin MCW Department of Otolaryngology and Communication Sciences.

Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.

Empowering induction therapy for locally advanced head and neck cancer A. Argiris1* & M. V. Karamouzis2 1Division of Hematology–Oncology, Department of.

Risk Stratification in Stage II Colon Cancer Patients Ramzi Amri, MD, PhD; Liliana G Bordeianou, MD, MPH; and David L Berger, MD Massachusetts General.

방사선종양학과 - 혈액종양내과 Joint Conference 경희의료원 방사선종양학과 R4 공 문 규.

Department of Hemato-Oncology MGR review.  Epithelial carcinoma of the head and neck  arised from the mucosal surfaces in the head and meck area  squamous.

Taipei Veterans General Hospital Practices Guidelines Oncology Oral Cavity Cancer Version

Radiation Therapy for the Management of Oral Cavity and Oropharyngeal Cancers Samir Narayan, M.D. 9/9/2016.

Management of metastatic and recurrent head and neck cancer

Treatment options for HPV+ disease

Compassionate People World Class Care

Figure 1. Age Standardized Rate of Oropharyngeal Squamous Cell Carcinoma (OPSCC) in the UK, Data courtesy of the UK HPV Prevalence Study (1)

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction

The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized and Advanced Prostate Cancer David M. Spellberg M.D., FACS Naples.

Cancer of the Head and Neck and HPV Infection

Figure 5 Schematic illustration of different clinical trial designs

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer Howard West, MD, Rogerio Lilenbaum, MD, David Harpole,

Figure 2 Nonmalignant tissue can be spared from radiation

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Clinical Radiation Oncology NMT232 L 10

Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer Chul Kim, MD, MPH, Chuong D. Hoang, MD,

Jay Douglas Department of Radiation Oncology

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Management of Mediastinal Relapse after Treatment with Stereotactic Body Radiotherapy or Accelerated Hypofractionated Radiotherapy for Stage I/II Non–Small-

Treatment of Stage III Non-small Cell Lung Cancer

Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &

A–J, Pretreatment (A) and post–cycle 3 (B) computed tomographic imaging for patient A–J, Pretreatment (A) and post–cycle 3 (B) computed tomographic.

Presentation transcript:

General principles for treatment selection Jeffrey Myers MD PhD

General principles for treatment selection Site/subsite Stage Histology Biomarkers

Site

Tonsil Base of tongue Pharyngeal wall Soft palate Subsites

Histology –Grade Differentiation Status Ploidy –Other Findings Perineural Invasion Extracapsular spread Margin

Biomarkers HPV p16 EGFR Genomic/Proteomic Profiles

Molecular Classification Identifies a Subset of Human Papillomavirus– Associated Oropharyngeal Cancers With Favorable Prognosis Journal of Clinical Oncology, Vol 24, No 5 (February 10), 2006: pp

EGFR and SCCHN Treatment Outcomes L Milas & KK Ang J Clin Oncol AK El-Naggar, JJ Lee, L Mao J Clin Oncol KK Ang & L Milas Cancer Res. 2002

Stage T- Stage –Tx –Tis –T 1-2 –T 3-4 N-Stage –N0 –N1 –>N1 –ECS Overall Stage Other Considerations –Depth of Invasion –Growth Pattern

Myers,. Cancer 2002; 92(12):3030

Greenberg. Cancer 2003;97:1464.

Overall Stage and Treatment Selection: Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer N Engl J Med Oct 25;357(17):

Treatment Options Surgery Radiation Therapy Systemic Therapy Chemoradiotherapy –Induction –Concurrent –Induction followed by Concurrent –Adjuvant Targeted Molecular Therapy + Radiotherapy

Surgery-Primary/Neck Staging Surgery Debulking Surgery Definitive Surgery Open Surgery –Transoral Microsurgery –Robotic surgery Planned Surgery after non-surgical Therapy Salvage Surgery

Radiation Therapy –Particles Electrons Neutrons Protons –Fields -Parallel Opposing -IMRT -Stereotactic Radiosurgery –Fractionation Conventional Hyperfractionation Concomitant Boost Hypofractionation

Systemic Therapy: Chemotherapy/Biologic Therapy Chemoprevention Induction Concomitant Adjuvant

Summary Site, Stage, and Histology are our main guides for selecting therapy More Level I evidence is needed to guide the use of biomarkers in impacting treatment choices The menu of treatment options is large and individualized treatment decisions should be made by experienced multi-disciplinary teams keeping oncologic and quality of life issues in mind Where possible it is best to use the fewest modalities needed to effect a cure